{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Number of participants overall survival following stem cell transplant. Overall survival is defined as number participants alive following stem cell transplant","groups":[{"description":"Subjects received a nonmyeloablative preparative regimen of alemtuzumab 30mg IV three times a week for two weeks followed by fludarabine 25mg/m\\^2/day for five days followed by a PBPC graft targeted to deliver ≥ 5x10\\^6 CD34+ cells/kg. Cyclosporine A (CSA) for GVHD prophylaxis will be used initially with target CSA levels in the therapeutic range (200 -400 ng/ml).","id":"OG000","title":"Stem Cell Transplant Therapy With Campath-1H"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Number of Participants Overall Survival","type":"SECONDARY","unitOfMeasure":"Participants"}